|
| 36849411 | Exploiting the Receptor-Binding Domains of R-Spondin 1 to Target Leucine-Rich Repeat-Containin G-Coupled Protein Receptor 5-Expressing Stem Cells in Ovarian Cancer. | J Pharmacol Exp Ther | 2023 |
| 36888611 | Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma. | PLoS One | 2023 |
| 34843717 | Luxeptinib disables NLRP3 inflammasome-mediated IL-1β release and pathways required for secretion of inflammatory cytokines IL-6 and TNFα. | Biochem Pharmacol | 2022 |
| 35499387 | Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia. | Mol Cancer Ther | 2022 |
| 35715421 | Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancer. | NPJ Syst Biol Appl | 2022 |
| 33492953 | Therapeutic Targeting of Tumor Cells Rich in LGR Stem Cell Receptors. | Bioconjug Chem | 2021 |
| 32466781 | Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. | J Transl Med | 2020 |
| 33109540 | WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer. | Anticancer Res | 2020 |
| 31251556 | Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy. | ACS Appl Mater Interfaces | 2019 |
| 31267590 | Securing the Payload, Finding the Cell, and Avoiding the Endosome: Peptide-Targeted, Fusogenic Porous Silicon Nanoparticles for Delivery of siRNA. | Adv Mater | 2019 |
| 29626126 | APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency. | Mol Cancer Ther | 2018 |
| 30555899 | Tumor Retention of Enzyme-Responsive Pt(II) Drug-Loaded Nanoparticles Imaged by Nanoscale Secondary Ion Mass Spectrometry and Fluorescence Microscopy. | ACS Cent Sci | 2018 |
| 29626127 | APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells. | Mol Cancer Ther | 2018 |
| 29416699 | LGR5 and LGR6 in stem cell biology and ovarian cancer. | Oncotarget | 2017 |
| 28341300 | A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. | Gynecol Oncol | 2017 |
| 27022832 | Cellular Delivery of Nanoparticles Revealed with Combined Optical and Isotopic Nanoscopy. | ACS Nano | 2016 |
| 27157188 | Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity. | Metallomics | 2016 |
| 26071630 | A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. | J Control Release | 2015 |
| 26503202 | Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery. | J Clin Oncol | 2015 |
| 26155939 | Cisplatin inhibits MEK1/2. | Oncotarget | 2015 |
| 26205368 | The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2). | Metallomics | 2015 |
| 24475288 | Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells. | PLoS One | 2014 |
| 25485574 | Integrin αV control of Cu homeostasis and cisplatin sensitivity. | Cell Cycle | 2014 |
| 25344320 | Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin. | Cell Commun Signal | 2014 |
| 24967972 | Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4. | Biochem Pharmacol | 2014 |
| 25174950 | Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway. | Oncol Rep | 2014 |
| 24522273 | Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. | Metallomics | 2014 |
| 24422495 | Dynamics of soft nanomaterials captured by transmission electron microscopy in liquid water. | J Am Chem Soc | 2014 |
| 24475900 | Tumor infiltrating B-cells are increased in prostate cancer tissue. | J Transl Med | 2014 |
| 24447817 | Characterization of a monoclonal antibody capable of reliably quantifying expression of human Copper Transporter 1 (hCTR1). | J Trace Elem Med Biol | 2014 |
| 23053666 | Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. | Mol Pharmacol | 2013 |
| 23933660 | In vivo time-gated fluorescence imaging with biodegradable luminescent porous silicon nanoparticles. | Nat Commun | 2013 |
| 23805314 | Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4. | PLoS One | 2013 |
| 23803742 | The role of metal binding and phosphorylation domains in the regulation of cisplatin-induced trafficking of ATP7B. | Metallomics | 2013 |
| 21988542 | Effects of solution concentration on the physicochemical properties of a polymeric anticancer therapeutic. | Mol Pharm | 2012 |
| 23097631 | Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. | Neoplasia | 2012 |
| 22710939 | Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A. | Mol Pharmacol | 2012 |
| 22842628 | Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling. | Biochem Pharmacol | 2012 |
| 22446624 | A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. | Gynecol Oncol | 2012 |
| 22459168 | The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin. | J Inorg Biochem | 2012 |
| 22569840 | An all-atom model of the structure of human copper transporter 1. | Cell Biochem Biophys | 2012 |
| 20930109 | Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. | Mol Pharmacol | 2011 |
| 21995420 | Aggregation properties of a polymeric anticancer therapeutic: a coarse-grained modeling study. | J Chem Inf Model | 2011 |
| 21885863 | A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. | Mol Cancer Ther | 2011 |
| 21630444 | Cisplatin-loaded porous Si microparticles capped by electroless deposition of platinum. | Small | 2011 |
| 21303546 | Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency. | BMC Cancer | 2011 |
| 21360176 | Coarse-grained modeling study of nonpeptide RGD ligand density and PEG molecular weight on the conformation of poly(γ-glutamyl-glutamate) paclitaxel conjugates. | J Mol Model | 2011 |
| 21327682 | Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. | Cancer Chemother Pharmacol | 2011 |
| 21452822 | Porous silicon nanoparticle photosensitizers for singlet oxygen and their phototoxicity against cancer cells. | ACS Nano | 2011 |
| 19685054 | Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. | Cancer Chemother Pharmacol | 2010 |